Clinical Trial Update: Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC [Phase 3]

View source ↗

Summary

Phase III trial update for Trans-Arterial Chemo-Embolization (TACE) adjuvant therapy in hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: COMPLETED